

G1T38: EXPERIMENTAL TREATMENT FOR EPIDERMAL GROWTH FACTOR RECEPTOR MUTANT (EGFRM) NON-SMALL CELL LUNG CANCER (NSCLC)

Scientific rationale and therapeutic potential

G1T38 is a potent and selective oral CDK4/6 inhibitor designed to block the growth of cancer cells and induce tumor-cell death when combined with other anti-cancer agents, such as Tagrisso®. G1T38 has the potential to be best-in-class versus other oral CDK4/6 inhibitors.

Preclinical rationale (see: [Publications](#))

- published preclinical data demonstrating G1T38 is more potent and has less toxicity than other oral CDK4/6 inhibitors in development;
- preclinical data presented at the AACR 2018 annual meeting demonstrated that G1T38 can enhance the efficacy of EGFRi in NSCLC models.

G1 is recruiting patients for a Phase 1b/2 trial in EGFRm NSCLC

G1T38-03 Trial

- EGFRm non-small cell lung cancer
- multi-center, randomized, open-label
- G1T38 + Tagrisso®
- approximately 145 patients
- ClinicalTrials.gov identifier: [NCT03455829](#)